A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 11, 2009

Primary Completion Date

September 25, 2009

Study Completion Date

September 25, 2009

Conditions

Infections, Bacterial

Interventions

DRUG

GSK1322322/placebo

GSK1322322/placebo escalating doses from 500mg to 1500mg

DRUG

GSK1322322/placebo and midazolam

GSK1322322/placebo and 5mg midazolam

Trial Locations (1)

GSK Investigational Site, Randwick